Selexis CHO Cells in Suspension-1

Archives 2021

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

 

NOVEMBER 1, 2021
3 min read

Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

Geneva, Switzerland, November 1, 2021 – Selexis SA, a JSR Life Sciences company, today announced that business and...

Read More
JUNE 29, 2021
3 min read

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Geneva, Switzerland, and Durham, NC – June 29, 2021 – Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences...

Read More
JUNE 1, 2021
2 min read

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of...

Read More
MAY 27, 2021
3 min read

Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

Geneva, Switzerland, May 27, 2021 – Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work® ...

Read More
MARCH 24, 2021
3 min read

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service...

Read More
MARCH 18, 2021
3 min read

SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program

Geneva, Switzerland, March 18, 2021 – Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company...

Read More
MARCH 16, 2021
2 min read

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and...

Read More
MARCH 9, 2021
3 min read

Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate

Geneva, Switzerland, and Boston, Mass., March 9, 2021 – Selexis SA and Boston Immune Technologies and Therapeutics...

Read More
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

October 31, 2022

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

Read More
September 8, 2022

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Read More

Copyright© 2022 Selexis SA. All Rights Reserved.